NO303630B1 - Fenylsubstituerte 1,4-dihydropyridiner, medikament for behandling av sentraldegenerative tilstander og depresjoner og farmas°ytisk preparat omfattende de nevnte dihydropyridinene - Google Patents

Fenylsubstituerte 1,4-dihydropyridiner, medikament for behandling av sentraldegenerative tilstander og depresjoner og farmas°ytisk preparat omfattende de nevnte dihydropyridinene

Info

Publication number
NO303630B1
NO303630B1 NO944788A NO944788A NO303630B1 NO 303630 B1 NO303630 B1 NO 303630B1 NO 944788 A NO944788 A NO 944788A NO 944788 A NO944788 A NO 944788A NO 303630 B1 NO303630 B1 NO 303630B1
Authority
NO
Norway
Prior art keywords
dihydropyridines
phenyl
substituted
depressions
drug
Prior art date
Application number
NO944788A
Other languages
English (en)
Norwegian (no)
Other versions
NO944788D0 (no
NO944788L (no
Inventor
Heinrich Meier
Wolfgang Hartwig
Bodo Junge
Rudolf Schohe-Loop
Zhan Gao
Bernard Schmidt
Maarten De Jonge
Teunis Schuurman
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4342194A external-priority patent/DE4342194A1/de
Priority claimed from DE4342196A external-priority patent/DE4342196A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO944788D0 publication Critical patent/NO944788D0/no
Publication of NO944788L publication Critical patent/NO944788L/no
Publication of NO303630B1 publication Critical patent/NO303630B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
NO944788A 1993-12-10 1994-12-09 Fenylsubstituerte 1,4-dihydropyridiner, medikament for behandling av sentraldegenerative tilstander og depresjoner og farmas°ytisk preparat omfattende de nevnte dihydropyridinene NO303630B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4342194A DE4342194A1 (de) 1993-12-10 1993-12-10 Halogen-phenyl-substituierte 1,4-Dihydropyridine
DE4342196A DE4342196A1 (de) 1993-12-10 1993-12-10 Neue 4-Phenyl-substituierte 1,4-Dihydropyridine

Publications (3)

Publication Number Publication Date
NO944788D0 NO944788D0 (no) 1994-12-09
NO944788L NO944788L (no) 1995-06-12
NO303630B1 true NO303630B1 (no) 1998-08-10

Family

ID=25931955

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944788A NO303630B1 (no) 1993-12-10 1994-12-09 Fenylsubstituerte 1,4-dihydropyridiner, medikament for behandling av sentraldegenerative tilstander og depresjoner og farmas°ytisk preparat omfattende de nevnte dihydropyridinene

Country Status (25)

Country Link
US (2) US6239155B1 (ko)
EP (1) EP0657432B1 (ko)
JP (3) JP3959127B2 (ko)
KR (1) KR100355973B1 (ko)
CN (1) CN1109875A (ko)
AT (1) ATE234286T1 (ko)
AU (1) AU696925B2 (ko)
CA (1) CA2137623C (ko)
CZ (1) CZ288393B6 (ko)
DE (1) DE59410255D1 (ko)
DK (1) DK0657432T3 (ko)
ES (1) ES2193148T3 (ko)
FI (1) FI107920B (ko)
HU (1) HU224442B1 (ko)
IL (1) IL111923A (ko)
MX (1) MX9409573A (ko)
MY (1) MY117887A (ko)
NO (1) NO303630B1 (ko)
NZ (1) NZ270085A (ko)
PL (1) PL306158A1 (ko)
PT (1) PT657432E (ko)
RU (1) RU2155751C2 (ko)
SK (1) SK283409B6 (ko)
TW (1) TW300218B (ko)
UA (1) UA37211C2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193148T3 (es) * 1993-12-10 2003-11-01 Bayer Ag 1,4-dihidropiridinas sustituidas con fenilo con actividad cerebral.
LV12200B (lv) * 1997-07-03 1999-04-20 Gunārs DUBURS Antidiabētisks līdzeklis
WO2005023768A1 (en) * 2003-09-11 2005-03-17 Sanmar Speciality Chemicals Limited An improved process for the preparation of pure nisoldipine
CA2708118A1 (en) * 2007-12-14 2009-06-25 Merck Sharp & Dohme Corp. Mineralocorticoid receptor modulators

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963186C3 (de) * 1969-12-17 1979-02-15 Bayer Ag, 5090 Leverkusen Schwefelhaltige 1,4-Dihydropyridin-33-dicarbonsäureester
DE1963188A1 (de) * 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US3932646A (en) * 1971-04-10 1976-01-13 Farbenfabriken Bayer Ag Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylate
DE2117573C3 (de) * 1971-04-10 1978-07-27 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von unsymmetrischen l,4-Dihydropyridin-3,5dicarbonsäureestern, sowie ihre Verwendung als Arzneimittel
DE2117572C3 (de) * 1971-04-10 1980-03-20 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin ^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US3966946A (en) * 1973-06-12 1976-06-29 Smith Kline & French Laboratories Limited 1,4-Dihydropyridine compounds in treating hypertension
GB1425729A (en) * 1973-06-12 1976-02-18 Smith Kline French Lab 1,4-dihydropyridine compounds
DE2815578C2 (de) 1978-04-11 1986-01-16 Bayer Ag, 5090 Leverkusen Neue pharmazeutische Verwendung von Nimodipin
SE429652B (sv) * 1978-06-30 1983-09-19 Haessle Ab 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester
DE2935451A1 (de) 1979-09-01 1981-03-19 Bayer Ag, 5090 Leverkusen Optisch aktive 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arneimittel
DE3018259A1 (de) * 1980-05-13 1981-11-19 Bayer Ag, 5090 Leverkusen 1,4-dihydropyridine mit unterschiedlichen substituenten in 2- und 6-position, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3208628A1 (de) 1982-03-10 1983-09-22 Bayer Ag, 5090 Leverkusen Neue verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE3209274A1 (de) * 1982-03-13 1983-09-15 Bayer Ag, 5090 Leverkusen Pyridincarbonsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE3209276A1 (de) * 1982-03-13 1983-09-15 Bayer Ag, 5090 Leverkusen Arzneimittel mit antihypoxischer und ischaemie-protektiver wirkung
DE3239273A1 (de) 1982-10-23 1984-04-26 Bayer Ag, 5090 Leverkusen Tetrahydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
JPS6094963A (ja) * 1983-10-31 1985-05-28 Teijin Ltd １，４−ジヒドロピリジン−３，５−ジカルボン酸ジエステル誘導体及びその製造法
US5137889A (en) 1983-12-02 1992-08-11 Otsuka Pharmaceutical Co., Ltd. Dihydropyridine derivatives and process for preparing the same
DE3514865A1 (de) * 1985-04-25 1986-11-06 Bayer Ag, 5090 Leverkusen 1,4-dihydropyridin-derivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3544211A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Neue, fluorhaltige 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
IT1204459B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
DE3629545A1 (de) * 1986-08-30 1988-03-10 Bayer Ag Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE3718398A1 (de) 1987-06-02 1988-12-22 Troponwerke Gmbh & Co Kg Neue kombinationspraeparate mit antidepressiver wirkung
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
NO890046L (no) * 1988-01-20 1989-07-21 Bayer Ag Disubstituerte pyridiner.
DE3806277A1 (de) 1988-02-27 1989-09-07 Troponwerke Gmbh & Co Kg Verwendung von 1,4-dihydropyridin-derivaten
KR940003492B1 (ko) * 1988-10-27 1994-04-23 주식회사 유한양행 1,4-디하이드로피리딘유도체 및 그의 제조방법
JPH02149563A (ja) * 1988-11-30 1990-06-08 Nisshin Flour Milling Co Ltd ２−ハロエトキシカルボニル基を含有する１，４−ジヒドロピリジン誘導体の製造法
JPH03157369A (ja) * 1989-08-02 1991-07-05 Kaken Pharmaceut Co Ltd １，４―ジヒドロピリジン誘導体、その製造法およびそれを有効成分とする脳機能改善剤
DE4011695A1 (de) * 1990-04-11 1991-10-17 Bayer Ag Verwendung von n-alkylierten 1,4-dihydropyridindicarbonsaeureestern als arzneimittel, neue verbindungen und verfahren zu ihrer herstellung
DE4125271A1 (de) * 1991-07-31 1993-02-11 Bayer Ag Neue n-alkylierte 1,4-dihydropyridindicarbonsaeureester
WO1993006082A1 (en) * 1991-09-13 1993-04-01 Merck & Co., Inc. Process for the preparation of 4-substituted-1,4-dihydropyridines
US5310917A (en) * 1991-09-13 1994-05-10 Merck & Co., Inc. Process for the preparation of 4-substituted-1,4-dihydropydrines
DK0595164T3 (da) * 1992-10-30 1997-05-26 Bayer Ag 4-Heterocyclophenyl-substituerede dihydropyridiner
ES2193148T3 (es) * 1993-12-10 2003-11-01 Bayer Ag 1,4-dihidropiridinas sustituidas con fenilo con actividad cerebral.

Also Published As

Publication number Publication date
ES2193148T3 (es) 2003-11-01
US20010034451A1 (en) 2001-10-25
ATE234286T1 (de) 2003-03-15
HU224442B1 (hu) 2005-09-28
AU8030594A (en) 1995-06-15
DK0657432T3 (da) 2003-07-07
CZ288393B6 (en) 2001-06-13
NZ270085A (en) 1996-10-28
PL306158A1 (en) 1995-06-12
MX9409573A (es) 1997-02-28
IL111923A0 (en) 1995-03-15
HUT70400A (en) 1995-10-30
TW300218B (ko) 1997-03-11
JP2007084567A (ja) 2007-04-05
KR100355973B1 (ko) 2002-12-26
PT657432E (pt) 2003-07-31
MY117887A (en) 2004-08-30
FI107920B (fi) 2001-10-31
KR950017959A (ko) 1995-07-22
EP0657432A1 (de) 1995-06-14
JP2007091750A (ja) 2007-04-12
RU94043812A (ru) 1996-10-27
DE59410255D1 (de) 2003-04-17
EP0657432B1 (de) 2003-03-12
NO944788D0 (no) 1994-12-09
IL111923A (en) 1999-12-22
JP3959127B2 (ja) 2007-08-15
RU2155751C2 (ru) 2000-09-10
US6239155B1 (en) 2001-05-29
US6630494B2 (en) 2003-10-07
SK153194A3 (en) 1995-07-11
JPH07196614A (ja) 1995-08-01
CA2137623C (en) 2005-07-26
HU9403552D0 (en) 1995-02-28
CA2137623A1 (en) 1995-06-11
FI945778A (fi) 1995-06-11
AU696925B2 (en) 1998-09-24
CN1109875A (zh) 1995-10-11
UA37211C2 (uk) 2001-05-15
CZ310994A3 (en) 1995-09-13
SK283409B6 (sk) 2003-07-01
NO944788L (no) 1995-06-12
FI945778A0 (fi) 1994-12-08

Similar Documents

Publication Publication Date Title
IL90435A (en) 4-(quinoline-2-yl-methoxy) phenylacetic acid derivatives, their preparation and pharmaceutical compositions containing them
HUT64065A (en) Process for producing quinolone- and naphthyridonecarboxylic acid derivatives and pharmaceutical compositions comprising same as active ingredient
IL104006A0 (en) Azaheterocyclylmethyl-chromans,their preparation and pharmaceutical compositions containing them
HUT53068A (en) Process for producing benzoic acid and phenylacetic acid derivatives and pharmaceutical compositions comprising such active ingredient
IL109604A0 (en) Substituted mono- and bipyridylmethyl- pyridones, process for their preparation and pharmaceutical compositions containing them
IL90052A (en) :-substituted 4-(quinolin- 2-yl-methoxy) phenylacetic acids and esters, their preparation and pharmaceutical compositions containing them
DE3872739D1 (de) Arzneimittel mit langsamer freisetzung.
CA2129995A1 (en) Piperidinyl thiacyclic derivatives
DE69818286D1 (de) Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen
HUT70150A (en) Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines, pharmaceutical compositions containing them and method for its preparation
NO944531L (no) Diaminsalter av clavulansyre
NO303630B1 (no) Fenylsubstituerte 1,4-dihydropyridiner, medikament for behandling av sentraldegenerative tilstander og depresjoner og farmas°ytisk preparat omfattende de nevnte dihydropyridinene
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
DE3883335D1 (de) Brenzcatechincarbonsaeurederivate, ihre herstellung und verwendung als wirkstoffe fuer arzneimittel.
IL108997A0 (en) Heterotricyclically substituted phenyl-cyclohexane-carboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
IL102670A0 (en) N-alkylated 1,4-dihydropyridine dicarboxylic acid esters,their preparation and pharmaceutical compositions containing them
IL107414A0 (en) 4-heterocyclyl-substituted dihydropyridines, their preparation and pharmaceutical compositions comprising them
AU3108393A (en) Specific 1,4-dihydropyridine-3,5-dicarboxylic acid ester, process for its preparation and its pharmaceutical use
EP0523013A3 (en) Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases
ES2191671T3 (es) Esteres de 1,4-dihidropiridina 4-fenil-3-sustituidos.
HU9802896D0 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
DE69111530D1 (de) Pyridincarbonsäure-Amid-Derivate und diese enthaltende pharmazeutische Zusammensetzungen.
AU4164693A (en) Specific 1,4-dihydropyridine-3,5-dicarboxylic acid ester, process for its preparation and its pharmaceutical use
CA2021501A1 (en) Topical pharmaceutical compositions

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees